Hematology-Oncologyacute myeloid leukemiaCDK inhibition
Enhancing Acute Myeloid Leukemia Treatment: Dual CDK2 and CDK4/6 Inhibition Targets Cell Cycle and Rb/E2F Signaling
By MedXY|Jun 25, 2026
Dual inhibition of CDK2 and CDK4/6 demonstrates synergistic anti-leukemic effects in AML by suppressing the Rb/E2F axis, offering a promising therapeutic strategy to improve outcomes in this challenging hematologic malignancy.